HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis

[1]  G. Schulert,et al.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. , 2015, Annual review of medicine.

[2]  D. Rigante,et al.  The Systemic‐Onset Variant of Juvenile Idiopathic Arthritis Needs to Be Recorded as an Autoinflammatory Syndrome: Comment on the Review by Nigrovic , 2014, Arthritis & rheumatology.

[3]  Francis Guillemin,et al.  Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. , 2014, Joint, bone, spine : revue du rhumatisme.

[4]  A. Martini.  Systemic juvenile idiopathic arthritis. , 2012, Autoimmunity reviews.

[5]  P. Woo,et al.  Concise Report , 2022 .

[6]  Sampath Prahalad,et al.  Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. , 2012, Arthritis and rheumatism.

[7]  C. Macaubas,et al.  Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions , 2011, Nature Reviews Rheumatology.

[8]  P. Zhang,et al.  Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk , 2011, Nature Immunology.

[9]  G. Ruthel,et al.  Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules , 2011, PloS one.

[10]  R. Cron,et al.  Combination Therapy of Abatacept and Anakinra in Children with Refractory Systemic Juvenile Idiopathic Arthritis: A Retrospective Case Series , 2011, The Journal of Rheumatology.

[11]  Carl D Langefeld,et al.  Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. , 2010, Arthritis and rheumatism.

[12]  J. Stockman.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2010 .

[13]  L. Rink,et al.  MHC class II molecules activate NFAT and the ERK group of MAPK through distinct signaling pathways in B cells , 2009, European journal of immunology.

[14]  A. Martini,et al.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2008, The Lancet.

[15]  A. Martini,et al.  The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. , 2008, Arthritis and rheumatism.

[16]  R. Cron,et al.  Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. , 2007, The Journal of rheumatology.

[17]  Lars Fugger,et al.  MHC class II proteins and disease: a structural perspective , 2006, Nature Reviews Immunology.

[18]  Patricia Woo,et al.  Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome , 2006, Nature Clinical Practice Rheumatology.

[19]  M. Suarez‐Almazor,et al.  International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[20]  S. Buisson,et al.  MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). , 2003, Blood.

[21]  P Woo,et al.  Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. , 2002, Rheumatology.

[22]  S. Louis Bridges,et al.  National Institute of Arthritis and Musculoskeletal and Skin Diseases , 2000 .

[23]  T. Sasazuki,et al.  Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes. , 1999, Arthritis and rheumatism.

[24]  S. Al-Sedairy,et al.  A mixed Th1/Th2 cell cytokine response predominates in systemic onset juvenile rheumatoid arthritis: immunoregulatory IL-10 function. , 1998, Clinical immunology and immunopathology.

[25]  A. Prieur,et al.  Major histocompatibility complex markers and disease heterogeneity in one hundred eight patients with systemic onset juvenile chronic arthritis. , 1996, Revue du rhumatisme.

[26]  P. Woo,et al.  Increased frequency of DR4 in systemic onset juvenile chronic arthritis. , 1992, Clinical and experimental rheumatology.

[27]  R. Geha,et al.  Transcriptional activation of IL-1 beta and tumor necrosis factor-alpha genes by MHC class II ligands. , 1991, Journal of immunology.

[28]  D. Glass,et al.  HLA gene frequencies in children and adults with systemic onset juvenile rheumatoid arthritis. , 1985, Arthritis and rheumatism.